Substitute for form 1449A/PTO

ATTORNEY'S DKT NO. APPLICATION NO. 032475-007 10/051,243

SURE

APPLICANT

Maurice ISRAEL et al.

FILING DATE

FILING DATE GROUP
JANUARY 22, 2002 UNASSIGNED

INFORMATION DISCLOSURE

EXAMENT BY APPLICANT

SER 2 0 20	n o	4						
	175年 社会		US PATENT DOC	JMENTS :				
Ear	U.S. Patent Document		A CASA CONTRACTOR OF THE PARTY	AND SERVE OF THE PARTY.	A STATE OF THE STA		Mark Page 1 Mark	1-45- Allega
Examiner		Kind Code	Name of Patentee or Applicant			Date of Publication		
Initials	Number	(if known)	of Cited Document			(MM-DD-YYYY)		
177	5,254,683	<b></b>	Chapdelaine et al.			10/19/1993		
	<u> </u>	<u> </u>	<u> </u>					
							-	
	<del></del>		<del> </del>					
ļ						-		<del>.</del>
		<del>                                     </del>	<del> </del>					
		<del> </del>	<del> </del>					
			<u> </u>					
				Participation of the Control of the	7.50 A	THE STATE OF THE STATE OF		年81350
			ON HABITAN KENEKO	CUMENTS:			推議官	
	Foreign Patent							
Examiner Initials	Number	Kind Code (if known)	Country	Country		ate of Publication (MM-DD-YYYY)	Yes	slation no
11111111	WO 98/51291	(ii Rite iii)	PCT			11/19/1998	(Eng	glish
(M)					language abstract)			
100	EP 0 631 777	<del></del>	EUROPE		<del></del>	01/04/1995		T
	EP 0 146 338	<del></del>	EUROPE			06/26/1985	+	<del> </del>
	EF 0 140 000	<del> </del>	20110. 2		<u> </u>	70/20/1303	+	<del>                                     </del>
ļ		<b></b>			<u> </u>		<del>                                     </del>	—
		<u> </u>	ļ		<u></u>		<del>                                     </del>	↓
			<u></u>		<u> </u>	· <u> </u>		↓
								<u> </u>
		NON P	KANTANTA TURING KANTANTAN	DOCUME	viis.			
	· Include		(in CAPITAL LETTERS),		The state of the s	appropriate), title of	the	Manager 1
Examiner	item (book,	magazine, jour	nal, serial, symposium, ca				ber(s),	
Initials	MAATTEL at al. "Nat	terrore reduces	publisher, city and/or co				- mausa	
(DD)	MATTEI et al., "Naftazone reduces glutamate cerebro spinal fluid levels in rats and glutamate release from mouse cerebellum synaptosomes," <i>Neuroscience Letters</i> , 1999, pp. 183-86, vol. 271, Elsevier Science Ireland Ltd., Ireland.							
(10)	AZZA et al., "Lipid Peroxidation and Lysosomal Integrity in Different Inflammatory Models in Rats: The Effects of							
	Indomethacin and Naftazone," Pharmacological Research, 1995, pp. 279-85, The Italian Pharmacological Society, Italy.							
164	ZICOT, "Etude multicentrique de l'efficacite et de la tolerance de la nattazone (Mediaven <sup>®</sup> 10 MG). Comparaison de deux schemas posologiques," <i>Revue Medicale De Liege</i> , April, 1993, pp. 224-28, France.							
	HERBER et al., "Reduction and Glucuronidation of Naftazone by Human and Rat Liver Microsomes," <i>Drug Metabolism</i>							
14/	and Disposition, 1995, pp. 1305-14, Vol. 23, No. 12, The American Society for Pharmacology and Experimental							
	Therapeutics, Bethe	sda, Maryland,	USA.					
ļ	-							
<b></b>								
<del></del>	<del></del>		<del></del>					
Supplier				D-4-				
Examiner Signature				Date Considered	1 %	23/03	-	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.